These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

821 related items for PubMed ID: 19115222

  • 1. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.
    Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P.
    Hepatology; 2009 Apr; 49(4):1151-7. PubMed ID: 19115222
    [Abstract] [Full Text] [Related]

  • 2. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study.
    Gheorghiţa VI, Caruntu FA, Curescu M, Olaru I, Radu MN, Colţan G, Streinu-Cercel A.
    J Gastrointestin Liver Dis; 2013 Mar; 22(1):27-32. PubMed ID: 23539387
    [Abstract] [Full Text] [Related]

  • 3. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
    Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Akarca US, Flisiak R, Verhey E, Van Vuuren AJ, Boucher CA, ter Borg MJ, Janssen HL.
    Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
    [Abstract] [Full Text] [Related]

  • 4. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
    Boglione L, Cusato J, Cariti G, Di Perri G, D'Avolio A.
    Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, Mach T, Boucher CA, Hansen BE, Zeuzem S, Janssen HL.
    Antivir Ther; 2012 Dec; 17(1):9-17. PubMed ID: 22267464
    [Abstract] [Full Text] [Related]

  • 7. Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B.
    Chen J, Zhang DH, Xu CR, Zhu MY, Yang ZT, Gong QM, Yu DM, Zhang XX.
    J Clin Virol; 2015 Nov; 72():88-94. PubMed ID: 26476325
    [Abstract] [Full Text] [Related]

  • 8. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
    Brunetto MR, Marcellin P, Cherubini B, Yurdaydin C, Farci P, Hadziyannis SJ, Rothe V, Regep L, Bonino F.
    J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
    [Abstract] [Full Text] [Related]

  • 9. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
    Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL.
    Hepatology; 2010 Oct; 52(4):1251-7. PubMed ID: 20830787
    [Abstract] [Full Text] [Related]

  • 10. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
    Tangkijvanich P, Komolmit P, Mahachai V, Sa-nguanmoo P, Theamboonlers A, Poovorawan Y.
    J Clin Virol; 2009 Oct; 46(2):117-23. PubMed ID: 19651540
    [Abstract] [Full Text] [Related]

  • 11. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
    Li MH, Hu LP, Zhang L, Lu Y, Shen G, Wu SL, Chang M, Mu CQ, Wu YZ, Yang M, Song SJ, Zhang SF, Hua WH, Xie Y, Cheng J, Xu DZ.
    Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
    [Abstract] [Full Text] [Related]

  • 12. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.
    Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, Liaw YF, Xie Q, Heathcote EJ, Chan HL, Janssen HL.
    Hepatology; 2013 Sep; 58(3):872-80. PubMed ID: 23553752
    [Abstract] [Full Text] [Related]

  • 13. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
    Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P.
    Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
    Peng CY, Lai HC, Li YF, Su WP, Chuang PH, Kao JT.
    Aliment Pharmacol Ther; 2012 Feb; 35(4):458-68. PubMed ID: 22225574
    [Abstract] [Full Text] [Related]

  • 16. [Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].
    Zhu YY, Wu YL, Chen J, Zheng Q, Dong J, Jiang JJ.
    Zhonghua Gan Zang Bing Za Zhi; 2012 Oct; 20(10):737-41. PubMed ID: 23207332
    [Abstract] [Full Text] [Related]

  • 17. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
    Ouzan D, Pénaranda G, Joly H, Khiri H, Pironti A, Halfon P.
    J Clin Virol; 2013 Dec; 58(4):713-7. PubMed ID: 24183313
    [Abstract] [Full Text] [Related]

  • 18. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL.
    PLoS One; 2015 Dec; 10(4):e0122259. PubMed ID: 25835020
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a.
    Moucari R, Martinot-Peignoux M, Mackiewicz V, Boyer N, Ripault MP, Castelnau C, Leclere L, Dauvergne A, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P.
    Antivir Ther; 2009 Dec; 14(8):1183-8. PubMed ID: 20032548
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.